This combination tablet contains Voglibose 0.3mg, Glimepiride 2mg, and Metformin HCl 500mg. It is designed for effective glycemic control in patients with type 2 diabetes mellitus, especially when diet, exercise, and single oral antidiabetic agents are insufficient. Voglibose: An alpha-glucosidase inhibitor that slows carbohydrate absorption, reducing postprandial blood sugar spikes. Glimepiride: A sulfonylurea that stimulates insulin release from pancreatic beta cells, lowering fasting and postprandial glucose. Metformin HCl: A biguanide that decreases hepatic glucose production and improves insulin sensitivity, helping maintain long-term blood sugar control. This combination therapy provides dual and postprandial glucose regulation, making it ideal for patients with poorly controlled blood sugar on monotherapy.
